Recursion Pharmaceuticals

RXRX

$
4.33
(
-5.5
%)
(
+
-5.5
%)
+
-49.0
%
2.21
NASDAQ

Last Price

12/12/25, 09:30 AM
 EDT

Margin of Safety

Future Compounder
$
2.21

PORTFOLIO CATEGORY

Modeled fair value

Up to 2.5%
$1.032 billion

Allocation Suggestion

Modeled fair value

Model Basis

LAST REFINED:
May 5, 2025
The current model INCLUDES the following assets and assumptions:
The current model is based on operating metrics, including:
  • REC-617 in advanced solid tumors driven by CDK7 (phase 1/2)
  • REC-4881 in familial adenomatous polyposis (phase 1/2)
The current model EXCLUDES the following assets:
  • REC-1245 in solid tumors (phase 1)
  • REC-3565 in B-cell malignancies (phase 1)
  • REC-4539 in small-cell lung cancer (SCLC) (phase 1)
  • REC-7735 in PI3K-alpha kinase mutant HR+/HER2- breast cancer (preclinical)
  • REC-102 in hypophosphatasia (preclinical)

Research Deep Dive

Last Updated:

Overview

Solt DB Invest will introduce Base Research for our coverage ecosystem over the next month to coincide with third-quarter 2023 earnings announcements. Check back soon!

Technology Platform

Pipeline

Portfolio

Opportunities & Advantages

Challenges & Risks

Development Risk 

Regulatory Risk 

Commercial Risk 

Dilution Risk 

Valuation Risk 

Geopolitical Risk 

Unique Risks 

Modeling Insights

News Flow & Timing